CAMBRIDGE

Cambridge University Press
978-0-521-86323-0 - Cancer of the Ovary
Edited by Rodney Reznek
Index
More information

Index

acute abdominal pain, treatment 150
  assessment 150
    intestinal obstruction, two level 151
    squashed stomach syndrome 152
adnexal masses, differential diagnosis 99
  ovarian cysts, simple 99, 100
    transvaginal scan 100
  benign cystadenomas 99
    Brenner tumours 104
    cell tumours, granulosa 103
    endometriomas 101
    functional cysts, haemorrhagic 100
    mature cystic teratoma, ovary 101
    pelvic masses 105
    peritoneal pseudocysts 104
    Rokitansky nodule 101
    thecomas, ovarian fibromas 103
    tubal origin, masses 104
    uterine fibroids 104
advanced disease, ultrasound-guided biopsy 106
  diagnosis, histological 106

carcinoma, ovary, CT 132–53
  uses, CT 132
carcinoma, primary 1
  databases, GLOBOCAN 2002 2
chemotherapy, disease, advanced, 83
  approaches, other treatment 84 (see also systemic)
  systemic 83
    cisplatin 83
    progression-free survival (PFS) 83
    Taxus brevifoia 83
chemotherapy, disease, early stage 82
  disease-free survival (DFS) 82
  International collaboration on ovarian neoplasms (ICON1) 83
chemotherapy, IDS patients 145
  bidimensional measurements, WHO criteria 145
    complete response unconfirmed (CRU) 145
    measurements, response 146
    response criteria in solid tumours (RECIST) 146
  interval debulking surgery (IDS) 145, 152
chemotherapy, debulking surgery (prior to) 144
  post-surgery, baseline 144
cysts, non-neoplastic 20
  types 20
cytoreductive surgery, primary 71
  cavitron ultrasonic aspirator (CUSA) 72
  chemotherapy or upfront surgery (CHORUS) 71, 74 (see also neoadjuvant chemotherapy, primary, delayed)
  Meigs 71
  Scottish randomised trial in ovarian cancer (SCOTROC) 73

detecting malignancy, ultrasound performance 105
  Doppler, combined morphology 106
  ultrasound, morphological/ Doppler 105, 106
disease, staging, defining extent 123
  adenocarcinoma, ovarian, recurrent 124
  bowel obstruction, ovarian cancer 125
  recurrent disease, detection, tumour response, residual disease, assessment 127
    computed tomography (CT) 128
  staging, accuracy 126
  tumour resectability 127

epidemiology, genetic 1
  ovarian cancer, susceptibility, genetic 3
    hereditary non-polyposis colorectal cancer (HNPCC) 5 (see also syndromes, familial cancer)
    polymorphism, human genomes, types 5
    single nucleotide polymorphism (SNPs) 5
    susceptibility genes, high penetrance 3
    susceptibility genes, high-risk 5
    susceptibility, low penetrance 5
    syndromes, familial cancer 3
  risks, familial 1
    Schildkraut, Thompson 2

hormonal factors, reproductive 6 (see also hormonal factors, reproductive, other)

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-86323-0 - Cancer of the Ovary
Edited by Rodney Reznek
Index
More information

hormonal factors, reproductive (Contd.)
hormone replacement therapy (HRT) 9–10
oestrogen therapy (ET) 9
infertility 8
lactation 7
late menopause, early menarche 6
parity 6
oral contraceptive (OC) pill 7–8
hormonal factors, reproductive 10
age 10
diet 12
endometriosis 11
powder, talcum 10
pelvic inflammatory disease (PID) 12
human papilloma virus (HPV) 12
polycystic ovarian syndrome (PCOS) 12, 13
follicle stimulating hormone (FSH) 12
luteinizing hormone (LH) 12
surgery, pelvic 11

induction chemotherapy, interval debulking 75
Gynecologic Oncology Group (GOG152) 75

laparotomy, staging 69
adjuvant chemotherapy in ovarian neoplasm (ACTION) 70
European Organisation for research and treatment of Cancer (EORTC) 70, 74, 75 (see also induction chemotherapy, interval debulking)
International Federation of Gynaecology and Obstetrics (FIGO) 69–70 (see also cytoreductive surgery, primary)
surgical staging, elements 70

malignancy, ultrasonic diagnosis 96
malignant features 96
adenocarcinoma, differentiated 96
carcinoma, endometrial 97
cystadenocarcinoma, mucinous 98
cystadenocarcinoma, serous 97, 101
transvaginal Doppler 98
primary malignancies, ultrasonic features 96
carcinomas, endometrioid 98
clear cell tumours 98
low malignant potential (borderline), epithelial tumours 98
tumours, germ cell 98
tumours, mucinous 97
tumours, serous 96
metastatic malignancy, ultrasonic features 99
monitoring, therapy 164
computed tomography (CT) 164
Guidelines to evaluate the response to treatment in solid tumors 165
response evaluation criteria in solid tumors (RECIST) 165
ultrasound (US) 164
MR imaging 112, 128 (see also ovarian cancer, MR imaging)

neoadjuvant chemotherapy, primary surgery 73–4
Royal College of Obstetricians and Gynaecologists (RCOG) 74

ovarian cancer 47, 69
silent killer 69
cancers, commonest 48
survival rates 48
ovarian cancer, epidemiology, 1–13
ovarian cancer, epithelial, surgical management 69–78
ovarian cancer, FDG-PET/CT 162–4
(see also monitoring, therapy)
tomography and computed tomography (PET/CT) 162–4
ovarian cancer, MR imaging 112–28
fat-saturated chemical shift 112
apparent diffusion coefficient (ADC) 113
echo planar diffusion weighted imaging (EPDWI) 113
fat-suppression sequences 112
STIR sequences 112
parallel imaging 112
radiofrequency (RF) 112
ovarian cancer, PET, CT 156
ovarian cancer, primary, FDG−PET imaging 158–60
low malignant potential (LMP) 158–60, 168
ovarian cancer, recommendations, summary, CT 152
role 152
pathway 152
ovarian cancer, recurrent, cytoreductive surgery 75
DESKTOP (AGO-OVAR) 76
EORTC (55963 – Larocson study) 75
ovarian cancer, recurrent, palliative surgery 76
model, Krebs and Gopelrud 77
ovarian cancer, relapsed 85
approaches, other treatment 88
approaches 89
therapies, endocrine, 88
therapies, novel 89
chemotherapy 85
anthracyclines 86
etoposide 85
gemcitabine 86
paclitaxel 85
topotecan 85
platinum agents, other 87
capecitabine 87
oxaliplatin 87
vinorelbine 87
response prediction 88
therapy, single-agent vs. combination 87
treatment, time 88 (see also tumour markers)
ovarian cancer, screening, 47–64
ovarian cancer, staging, ultrasound 107
screening 107
CA125 107–8
ovarian carcinoma, medical treatment 82
ovarian carcinoma, ultrasound 94

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-86323-0 - Cancer of the Ovary
Edited by Rodney Reznek
Index
More information

ovarian masses, MRI characteristics 115
general features, 115
tumours, smooth muscle/fibrotic component 116
specific features 119
cyst adenocarcinoma 120
dysgerminomas 122
epithelial tumours 119
metastases, ovarian 123
Rokitansky protuberance 122
teratomas, ovarian cystic 115, 121 (see also teratoma cystic, benign)
tumour, borderline 121
tumour, collision 121
tumour, germ cell 121
tumour, germ cell, mixed 121
tumour, Sertoli–Leydig cell 122
tumour, sex cord-stromal cell 122
ovarian neoplasm 20, 23 (see also cystadenoma, mucinous)
classification, ovarian tumours, WHO 20–2
ovarian masses 23
picket-fence 24, 26
ovarian tumours, borderline 24
ovarian tumours, histogenesis 24
tumours, transtional cell 24
carcinosarcoma 24
ovarian neoplasm, pathological features 20–42
ovarian tumours, epithelial, invasive 30
clinical patterns 32
dysgerminoma 37
placenta-like alkaline phosphatase (PLAP) 37
fibroma, thecoma 39–40
Meig's syndrome
ovarian carcinoma 30 (see also ovarian neoplasia, FIGO staging)
ovarian carcinoma, endometrioid 34
adenocarcinoma, endometrioid 35
carcinoma, clear cell 36
hob-nail 35
malignant mixed Mullerian tumour (MMMT) 35
ovarian carcinoma, mucinous 33
adenocarcinoma, mucinous 34
mucinous carcinoma 33
ovarian carcinoma, serous 32
adenocarcinoma, serous 33
cystadenocarcinoma serous 33
ovarian carcinoma, transitional cell, malignant Brenner 36
ovarian neoplasia, FIGO staging 31
ovarian tumours, germ cell 36
teratoma, mature 37
ovarian tumours, metastatic 40 (see also tumour, Kruckenberg)
lymphoma, Burkitt's 41
ovary, stromal tumours, sex cord 38
tumour, granulosa cell 38
tumour, Kruckenberg 40–1
tumours, Sertoli-Leydig cell 40, 41
tumour, yolk sac 38
Schiller-Duval bodies 38
ovarian tumours, mixed, epithelial benign 24
cystadenoma, endometroid 26–7
chocolate cysts 27
endometriosis 27
cystadenoma, mucinous 25, 26
tumour, serous, benign 25
cystadenoma, serous 24, 25
ovarian tumours, borderline epithelial 27
borderline ovarian neoplasm 28
budding 29
flow cytometry 29, 34
ovarian Brenner tumour 30
ovarian neoplasia, endometroid 30
ovarian neoplasia, mucinous 29
ovarian neoplasia, serous 28
peritoneal implants 28
tumour, Brenner 25, 27, 30, 36

pelvic mass, characterisation/diagnosis 113–14
lesions, adnexal 113–14
adnexal masses 113
benign endometriotic cyst, 116, 117
benign teratoma cystic, 115 (see also teratomas, ovarian cystic)
CA125 114, 128
Doppler techniques 114
ovarian tumours, malignant, MRI features 114
ovarian adenocarcinoma 119, 120
borderline tumour, serous papillary 118
peritoneal nodules 120
omental disease 120
positron emission tomography (PET) 156–60, 168
fluorodeoxyglucose (FDG) 156–9, 168
uptake 158, 160, 165–7
image analysis/procedures (PET), general 157
standardized uptake values (SUV) 157

recurrent disease, distant metastases/diagnosis 161
recurrent ovarian cancer, CT 148
coronal reconstruction 149
metastasis, recurrence, unusual sites, CT 150
remission confirmation, CT 146
requirements, screening test 47
positive predictive value (PPV) 49

screening cost 63 (see also UKCTOCS)
screening, techniques 49
modalities, other 55
radioimmunoscintigraphy 55
screening, multimodal 55
advantages 55
transvaginal ultrasound scanning (TVS) 53, 56, 57, 62
tumour markers 49
black box technology 54
breast cancer (BC) 62

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-86323-0 - Cancer of the Ovary
Edited by Rodney Reznek
Index
More information

screening, techniques (cont.)
CA125 49
colour flow Doppler (CD) 53, 62
epithelial ovarian cancer (EOC) 53, 62
family history (FH) 53
mass spectrometry (MS) 54
personal history (PMH) 62
randomised controlled trial (RCT) 53
risk of ovarian cancer (ROC) 50, 56
risk of ovarian cancer alogrithm (ROCA) 53
screening studies 51, 53 (see also target populations)
transabdominal ultrasound (TAS) 53
UKCTOCS, trial design 50, 56–7, 64
Ultrasound (USS) 53
ultrasound 54
methods, various 54
vaginal examination 49
staging (CT), initial diagnosis 132
CT-guided peritoneal biopsy, technique 142
image guided biopsy, criteria 142–3
needle core biopsies 143
neoadjuvant chemotherapy (before surgery), 132
ovarian cancer, untreated, CT features 134 (see also pre-surgical imaging, accuracy, evidence, current best)
appearances, primary 135
calcified, heavily 139
classification, FIGO 137
contrast-enhanced CT 138
disease, stage II 138
ovarian metastasis, appearances 136
radiological diagnostic oncology group (RDOG) 135, 138–9, 146, 148
pre-surgical imaging, accuracy, evidence, current best 138
biopsy, omental 141, 143
haematoxylin and eosin (H&F) staining 141, 143
image-guided needle core biopsy (IGB) 138–9
immunohistochemical stains 141
intervention (interval) debulking surgery (IDS) 140
lymphoma, non-Hodgkin 141
primary peritoneal carcinoma (PPC) 142
technique, CT 133–4
contrast medium nephrotoxicity (CMN) 134
suspected relapse (CT), follow-up 146
assessment, 147
National Cancer Institute (NCI) 146

target populations 58
population, general 63
population, high-risk 58
UK familial ovarian cancer screening study (UKFOCSS) 58
test acceptability 57

ultrasonic, technique 94
assessment, morphological 94
Doppler, examination 95
pulsatility index (PI) 95
resistance index (RI) 95
new developments 95

© Cambridge University Press www.cambridge.org